You just read:

Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis

News provided by

Can-Fite BioPharma Ltd.

01 Jun, 2016, 07:00 ET